dubai update, page-15

I think Awesome nailed it not a good market reaction but obvious that Matthew Lehman stepping in as CEO is flushing the dead wood Cripto-1 early pre-clinical program while always good for companies to have something to fall back on it's obvous it was just a drain on both capital & resources. Dubai i never really saw benefit in the first place despite many on here talking big things. It's a pretty standard move across the sector for a new CEO to shake things up once they take the reigns it's always their intention to control whats under the banner & push forward what they see as the points of value. PRR has pretty much been stripped right down to the core heading into Phase III trials the upside - we are giving it everything we've got, downside if C-Vac goes belly up there's not much to catch it.